DNDi E-news
April 2016   |   View Online

What role for DNDi in hepatitis C?

Viewpoint by Bernard Pécoul, Executive Director, DNDi

The barriers to accessing new hepatitis C drugs are a clear illustration of how today’s system of medical innovation is failing to deliver affordable treatments for people in need. »

DNDi, Pharco, and Malaysia’s Ministry of Health announce project to deliver affordable hepatitis C regimen

DNDi, Pharco Pharmaceuticals, and the Ministry of Health Malaysia announced at the International Liver Congress in Barcelona, Spain, that they signed agreements to test an affordable hepatitis C regimen with a target price of under $300.

DNDi’s R&D strategy for hepatitis C explained

DNDi released a paper outlining its R&D strategy for hepatitis C with details of the licensing terms reached with Pharco Pharmaceuticals, together with infographics on both the disease and the new project, and testimonies from Malaysian hepatitis C activists explaining their difficulties in accessing current treatments. »

Call for Papers:
PLOS WorldLeish-6 Collection

Once every four years, World Leish brings together scientists for the leading leishmaniasis event. DNDi is co-organizing World Leish 6, which takes place in Toledo, Spain, 16-20 May 2017. To accompany the event, the World Leish 6 Scientific Community and PLOS Collections call for research papers for a special PLOS WorldLeish-6 Collection, and DNDi will award prizes to 20 researchers. »


Malaria: Easier access to ASAQ and ASMQ treatment

Two recent developments promise to make access to malaria treatment easier: The PREGACT study presents much needed evidence that ACTs are safe and effective in pregnant women; and WHO Prequalification has extended the shelf life of ASMQ. »

The US Senate designates World Lymphedema Day

In a unanimous vote in the US Senate, the first annual “World Lymphedema Day” was marked on 6th March. The US Senate is the first legislature to officially recognize lymphedema as a major cause of global disability and suffering. »

Scientific Articles

Journal of Medicinal Chemistry:
Repositioning antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: Structure-activity studies on a preclinical candidate for visceral leishmaniasis »

BMC Paediatrics:
An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012 »

PLOS Neglected Tropical Diseases:
Eliminating the neglected tropical diseases: Translational science and new technologies »

Photo credits: Don Paul/DNDi, Maneesh Agnihotri/DNDi
DNDi y la farmacéutica Pharco prueban un tratamiento de bajo coste para la Hepatitis C con el apoyo de los gobiernos de Malasia y Tailandia »

DNDi e farmacêutica Pharco testam tratamento de baixo custo para hepatite C com apoio dos governos da Malásia e Tailândia »

BioMed Central: “Improving treatment availability for children with HIV”

Le Monde: “Hépatite C: un traitement à moins de 300 dollars à l’étude”

Science Africa: “Hepatitis C: DNDi, Malaysia, Thailand and Egypt’s Pharco pharmaceuticals collaborating on treatment”

France 24: “Hépatite C: l’Égypte ouvre la porte à un traitement à des prix défiant toute concurrence”
Bernama: “Kerjasama di antara kementerian kesihatan malaysia dengan DNDi untuk penyelidikan klinikal hepatitis C”

Healio: “DNDi announces Pharco partnership to reduce HCV treatment costs in Asia”

The Star Online: “Hepatitis C treatment at a fraction of the cost to be available soon”
Les Echos: “Hépatite C: bientôt un traitement à moins de 300 dollars”

The Guardian: “Hepatitis C treatment for under $300 coming soon”

El Pais: “Una ONG impulsa tratamientos contra la hepatitis C de menos de 300 euros”

The Guardian: “The price of health: the cost of developing new medicines“

SciDev.net: “Alta mortalidad por enfermedades desatendidas en Brasil”

Politico: “The Zika loopholes“

Rádis: "Por uma lógica inclusiva"
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2016 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book